Clinical Trial Update: PROPHY-VAP: Prevention of Early Ventilation Acquired Pneumonia (VAP) in Brain Injured Patients by a Single Dose of Ceftriaxone [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating a single-dose ceftriaxone to prevent early ventilation-acquired pneumonia in brain-injured patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Injury
• Ventilator-associated Pneumonia

Drugs mentioned

• ceftriaxone (ceftriaxone sodium)

Snippet

Sponsor: Poitiers University Hospital | Conditions: Early Ventilation Acquired Pneumonia in Brain Injured Patients | Phase 3 | Status: COMPLETED